EGFR and pancreatic neoplasm: For instance, targeted medicine that overexpress or mutation-related pathway dysfunction of epidermal growth factor receptor (EGFR) [6], vascular endothelial growth factor (VEGF) [7, 8], Notch [9], Hedgehog [10], mitogen-activated protein extracellular signal-regulated kinase (MEK) [11], and KRAS [12] common in pancreatic tumors are being extensively investigated.